Version 2 2024-11-27, 03:53Version 2 2024-11-27, 03:53
Version 1 2024-11-25, 20:55Version 1 2024-11-25, 20:55
journal contribution
posted on 2024-11-27, 03:53authored bySandeep Chhabra, Olan Dolezal, Brett Collins, Janet Newman, J Simpson, Ian MacreadieIan Macreadie, Ross Fernley, T Peat, James Swarbrick
The first structural and biophysical data on the folate biosynthesis pathway enzyme and drug target, 6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase (SaHPPK), from the pathogen Staphylococcus aureus is presented. HPPK is the second essential enzyme in the pathway catalysing the pyrophosphoryl transfer from cofactor (ATP) to the substrate (6-hydroxymethyl-7,8-dihydropterin, HMDP). In-silico screening identified 8-mercaptoguanine which was shown to bind with an equilibrium dissociation constant, K d, of ~13 µM as measured by isothermal titration calorimetry (ITC) and surface plasmon resonance (SPR). An IC 50 of ~41 µM was determined by means of a luminescent kinase assay. In contrast to the biological substrate, the inhibitor has no requirement for magnesium or the ATP cofactor for competitive binding to the substrate site. The 1.65 Å resolution crystal structure of the inhibited complex showed that it binds in the pterin site and shares many of the key intermolecular interactions of the substrate.<p></p>